Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar-Apr;17(2):176-81.
doi: 10.1097/MJT.0b013e3181c6c0b2.

Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway

Wenhui Zhu  1 , David S Zhu, Ravi A Madan, James L Gulley, William D Figg, William L Dahut
Affiliations
Review

Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway

Wenhui Zhu et al. Am J Ther. 2010 Mar-Apr.

Abstract

Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V.2. 2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed November 27, 2009.
    1. Huggins C, Hodges CV. Studies on prostatic cancer. Part I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Ural. 2002;168:9–12. - PubMed
    1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–244. - PubMed
    1. Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer. J Ural. 2006;175:27–34. - PubMed

Substances